Physician profile
Eric Grabel
NPI 1427406396
$937.70
in general payments reported to CMS, 2019-2025
11 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.41 · 2022: $455 · 2023: $172 · 2024: $50.51 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $231.66 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $159.71 | 2022-2023 | Camzyos |
| Recor Medical INC | $129.90 | 2025 | Paradise Ultrasound Renal Denervation System |
| Novartis Pharmaceuticals Corporation | $122.14 | 2021-2024 | |
| Pfizer INC. | $117.73 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.67 | 2022-2023 | Verquvo |
| Daiichi Sankyo INC. | $27.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2025 | Jardiance |
| Cumberland Pharmaceuticals, INC. | $17.36 | 2023 | Caldolor |
| Bayer Healthcare Pharmaceuticals INC. | $17.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Grabel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.